A phase 1 study of LOXO-292, a potent and highly selective RET inhibitor, in patients with RET-altered cancers Meeting Abstract


Authors: Drilon, A. E.; Subbiah, V.; Oxnard, G. R.; Bauer, T. M.; Velcheti, V.; Lakhani, N. J.; Besse, B.; Park, K.; Patel, J. D.; Cabanillas, M. E.; Johnson, M. L.; Reckamp, K. L.; Boni, V.; Loong, H. H. F.; Schlumberger, M.; Solomon, B.; Cruickshank, S.; Rothenberg, S. M.; Shah, M. H.; Wirth, L. J.
Abstract Title: A phase 1 study of LOXO-292, a potent and highly selective RET inhibitor, in patients with RET-altered cancers
Meeting Title: 54th Annual Meeting of the American Society of Clinical Oncology (ASCO)
Journal Title: Journal of Clinical Oncology
Volume: 36
Issue: 15 Suppl.
Meeting Dates: 2018 Jun 1-5
Meeting Location: Chicago, IL
ISSN: 0732-183X
Publisher: American Society of Clinical Oncology  
Date Published: 2018-05-20
Start Page: 6s
Language: English
ACCESSION: WOS:000442916000004
DOI: 10.1200/JCO.2018.36.15_suppl.102
PROVIDER: wos
Notes: Meeting Abstract: 102 -- Source: Wos
Altmetric Score
MSK Authors
  1. Alexander Edward Drilon
    136 Drilon